Futerman AH - Search Results

1

Futerman AH, Hardy J. Futerman AH, et al. Nature. 2016 Sep 22;537(7621):S160-1. doi: 10.1038/537S160a. Nature. 2016. PMID: 27652785 No abstract available.

2

RIPK3 as a potential therapeutic target for Gaucher's disease.

Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD, Platt FM, Cox TM, Futerman AH. Vitner EB, et al. Among authors: futerman ah. Nat Med. 2014 Feb;20(2):204-8. doi: 10.1038/nm.3449. Epub 2014 Jan 19. Nat Med. 2014. PMID: 24441827

3

Identification of Modifier Genes in a Mouse Model of Gaucher Disease.

Klein AD, Ferreira NS, Ben-Dor S, Duan J, Hardy J, Cox TM, Merrill AH Jr, Futerman AH. Klein AD, et al. Among authors: futerman ah. Cell Rep. 2016 Sep 6;16(10):2546-2553. doi: 10.1016/j.celrep.2016.07.085. Epub 2016 Aug 25. Cell Rep. 2016. PMID: 27568557 Free article.

4

Elevation of gangliosides in four brain regions from Parkinson's disease patients with a GBA mutation.

Blumenreich S, Nehushtan T, Barav OB, Saville JT, Dingjan T, Hardy J, Fuller M, Futerman AH. Blumenreich S, et al. Among authors: futerman ah. NPJ Parkinsons Dis. 2022 Aug 6;8(1):99. doi: 10.1038/s41531-022-00363-2. NPJ Parkinsons Dis. 2022. PMID: 35933559 Free PMC article.

5

Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation.

Blumenreich S, Nehushtan T, Kupervaser M, Shalit T, Gabashvili A, Joseph T, Milenkovic I, Hardy J, Futerman AH. Blumenreich S, et al. Among authors: futerman ah. NPJ Parkinsons Dis. 2024 Feb 8;10(1):33. doi: 10.1038/s41531-024-00645-x. NPJ Parkinsons Dis. 2024. PMID: 38331996 Free PMC article.

6

The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase.

Pelled D, Shogomori H, Futerman AH. Pelled D, et al. Among authors: futerman ah. J Inherit Metab Dis. 2000 Mar;23(2):175-84. doi: 10.1023/a:1005622001239. J Inherit Metab Dis. 2000. PMID: 10801059

7

Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide.

Bodennec J, Pelled D, Riebeling C, Trajkovic S, Futerman AH. Bodennec J, et al. Among authors: futerman ah. FASEB J. 2002 Nov;16(13):1814-6. doi: 10.1096/fj.02-0149fje. Epub 2002 Sep 5. FASEB J. 2002. PMID: 12223447

8

X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease.

Dvir H, Harel M, McCarthy AA, Toker L, Silman I, Futerman AH, Sussman JL. Dvir H, et al. Among authors: futerman ah. EMBO Rep. 2003 Jul;4(7):704-9. doi: 10.1038/sj.embor.embor873. EMBO Rep. 2003. PMID: 12792654 Free PMC article.

9

New directions in the treatment of Gaucher disease.

Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A. Futerman AH, et al. Trends Pharmacol Sci. 2004 Mar;25(3):147-51. doi: 10.1016/j.tips.2004.01.004. Trends Pharmacol Sci. 2004. PMID: 15019270 Review. No abstract available.

10

Phosphatidylcholine metabolism is altered in a monocyte-derived macrophage model of Gaucher disease but not in lymphocytes.

Trajkovic-Bodennec S, Bodennec J, Futerman AH. Trajkovic-Bodennec S, et al. Among authors: futerman ah. Blood Cells Mol Dis. 2004 Jul-Aug;33(1):77-82. doi: 10.1016/j.bcmd.2004.03.001. Blood Cells Mol Dis. 2004. PMID: 15223015

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

275 results

Search Page

Filters